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1. Introduction
   Cervical cancer is the third in incidence and the fourth in 
mortality among female cancers worldwide, with a variable 
prevalence according to the implementation of successful 
public health screening and treatment programs[1-3]. Recent 
molecular and epidemiological studies have shown that 
the human papillomavirus (HPV) is the main causative 
agent of cervical neoplasm[3]. Currently, genital HPV has 
been described to be a sexually transmitted disease of 
epidemiological importance, especially among the sexually 
active population, affecting a high percentage of persons, 
both women and men, living in underdeveloped countries[4]. 
Additionally, mother-to-child vertical transmission in the 
birth canal in mothers with genital condylomas has been 
suggested[5].
   Infection with one of the few oncogenic HPV types is 
necessary to cause invasive cervical cancer[6,7]. Currently, 
more than 120 different HPV types have been isolated and 
sequenced, of which about 40 are known to infect the 
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genital tract, and 18 are classified as carcinogens[8,9]. These 
later types are classified into two groups according to their 
oncogenic potential: those of high oncogenic risk including 
HPV16, 18, 23, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 
73 and 82, and types 6, 11, 40, 42, 43, 44, 54, 61, 69, 70, 72, 81 
and 89 regarded as possessing low oncogenic risk[10]. The 
most frequent HPV types associated with cancer and cervical 
dysplasia are HPV16, 18, 31, 33 and 45 accounting for 90% of 
these neoplasms[11].
   According to the World Health Organization[12], HPV 
infection is very common and most men and women are 
infected at some point of their life. Transmission does not 
necessarily require penetration but may occur with single-
skin contact of the genitals. Most infections disappear (90% 
of cases) during the two first years. Although other factors 
involved in cervical oncogenesis are required, prolongation 
of HPV infection may lead to the development of pre-
cancerous lesions and invasive cancers[13].
   The highest incidence of cervical cancer has been 
described in the Caribbean and Latin America with mortality 
observed mainly in women from 35 to 54 years of age[14]. 
In Peru, cervical cancer is the most common malignancy 
(24.9%), being closely related to socioeconomic level[15]. 
However, there are still no general epidemiological data 
to indicate the overall prevalence of HPV infection and 
its association with cervical neoplasia in this country. 
Traditional screening for HPV infection is crucial, but early 
detection of most cervical infections can be difficult since 
HPV is asymptomatic. In Peru, screening programs for HPV 
involve the traditional Papanicolaou (PAP) protocol. This 
technique has a high frequency of false negatives (between 
15%-50% cases) and false positives (30% cases), and the results 
should be considered with caution[15,16]. The introduction 
of molecular techniques in the cervical screening programs 
would help to improve the detection of pre-cancerous 
lesions and reduce equivocal results by employing better 
collection, preparation and testing methods[17]. Technologies 
such as PCR, which can amplify a specific HPV DNA sequence 
present in clinical samples and can detect 50-100 integrated 
virus/cell, is considered the most sensitive HPV detection 
technique worldwide[18].
   The aim of this study was to detect the most prevalent 
HPV genotypes in cervical smear samples of asymptomatic 
Peruvian women by analyzing the correlation between PAP-
stained cervical tests and PCR and sequencing of the E1 
region.
2. Materials and methods
2.1. Patients
   A prospective study was designed and coordinated by 
the Liga Peruana de Lucha Contra Cáncer de Cajamarca 
and Universidad Peruana de Ciencias Aplicadas (UPC) in 
Cajamarca, Peru, from October 2010 to May 2012. A total of 
254 women between 18 to 65 years old, attending routine 
gynecological examinations were included in this study. 
All the women were physically examined and cervical 
scrape samples were collected and stored for HPV testing. 
The women selected were asymptomatic with no previous 
history of HPV infection or any cervical neoplasia and were 
clinically normal. Exclusion criteria were pregnancy, severe 
gynecological bleeding and previous hysterectomy. A health 
worker informed all women about the study and informed 
consent was obtained from each of the participants included 
in the study. All the specimens studied were anonymous 
with coding numbers for analysis.
2.2. Sample collection and preservation
   Cervical cell samples were collected with a cytobrush from 
the ectocervix and endocervix of each woman and samples 
were preserved in a tube containing phosphate buffered 
saline (pH 8.6). The samples were then stored at -4 °C until 
being sent to the Molecular Biology Laboratory at UPC and 
Instituto de Investigación Nutricional. On receipt of the 
samples, the cytobrushes were discarded and the tubes were 
vortexed and centrifuged to pellet the cells, which were 
resuspended in 1 mL of phosphate buffered saline. Three 
aliquots of each fresh specimen were stored at -20 °C until 
testing.
2.3. PAP-stained cervical test
   PAP smears were obtained from the endocervix and 
ectocervix by scraping the squamous columnar cells with 
a wooden Ayre spatula. Using a cytology brush, cervical 
scrapings were spread over designated slides for each 
patient. The slides were fixed with ethanol and colored 
by the PAP technique. The samples were examined under 
a microscope by a pathologist and classified by the 
Bethesda system: atypical squamous cells of undetermined 
significance (ASCUS), low-grade squamous intraepithelial 
lesion (LSIL) (CIN1) and high-grade squamous intraepithelial 
lesion (HSIL) (CIN2 and CIN3)[19].
2.4. DNA extraction, amplification of HPV DNA and genotypes 
by sequencing
   Viral genomic DNA was extracted from a total volume of 200 
µL of the sample by the guanidinium thiocyanate extraction 
method[20] and the purified material was re-suspended 
in a final volume of 30 µL deionized water. Samples were 
electrophoresed on a 1% agarose gel to check the quality of 
the DNA.
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   HPV amplification was done using the primers and 
conditions described by Lurchachaiwong et al[21]. PCR 
products were analyzed on 2% agarose gel stained with 
ethidium bromide and bands were detected by UV 
transillumination (Kodack Logic 1500, USA). Positive 
specimens were confirmed by direct sequencing serving as 
the gold standard (Macrogen-Korea).
   The HPV genotypes were categorized into three groups: 
high and low risk, and others[6,7].
2.5. Statistical analysis
   Quantitative variables are reported as frequency (number 
or percentage of cases). Odds ratios (OR) with 95% confidence 
intervals (CI) were used to estimate precision. The χ2-test (or 
Fisher’s exact test when appropriate) was used to compare 
the distribution of categorical variables. Differences were 
considered significant at P<0.05. Statistical analyses were 
performed with SPSS software (Microsoft SPSS-PC+, v.15.0; 
SPSS, Chicago, IL, USA).
3. Results
   A total of 254 women between 18 to 65 years of age were 
included in this study. The women were from different 
locations in the province of Cajamarca, Peru.
   Regarding PAP smears, 94.9% of the cases had a normal 
morphology (negative PAP) and 5.1% showed an inflammatory 
pattern (positive PAP). However, the prevalence of HPV 
infection using the PCR method was 20.5% (Table 1), 
with statistically significant differences between the 
two techniques (P<0.000 1, χ2-test with Yates continuity 
correction).
Table 1
Comparison of HPV diagnosis by PAP smear and PCR to amplify the 
E1 viral gene.
Result PAP smear PCR
Cases (N) Frequency (%) Cases (N) Frequency (%)
Positive  13     5.1  52   20.5
Negative 241   94.9 202   79.5
Total 254 100.0 254 100.0
   Considering PCR as the “gold standard”, the specificity 
and sensitivity of PAP were 81% and 25%, respectively, 
with false negative and false positive rates of 75% and 19%, 
respectively.
   The results showed that 52/254 women (20.5%) had HPV 
infection, related to different HPV genotypes. Twelve different 
high risk genotypes were observed, with the HPV16 (38.5%) 
and the HPV39 (9.6%) genotypes being significantly more 
frequent (P<0.005); The remaining 10 high risk genotypes 
had low frequencies (from 1.9% to 3.8%). Five low risk viruses 
genotypes were detected with low incidence (1.9% to 3.8%). 
Finally, three genotypes (HPV34, 71 and 91) were classified as 
other HPV, of which the most significant (P<0.005) was HPV71 
with an incidence of 9.6% (Table 2).
Table 2
Distribution of HPV genotypes identified in asymptomatic women.
Viral type Cases 
(N)
Frequency 
(%)
95% CI χ2-test (P)
Low Upper
High risk HPV16 20 38.5 25.31 58.67 <0.000 1
HPV18  1  1.9  0.05 10.25 0.110 0
HPV31  2  3.8  0.47 13.20 0.029 7
HPV39  5  9.6  3.20 21.00 0.001 1
HPV51  1  1.9  0.05 10.25 0.110 0
HPV52  2  3.8  0.47 13.20 0.029 7
HPV53  1  1.9  0.05 10.25 0.110 0
HPV56  1  1.9  0.05 10.25 0.110 0
HPV66  2  3.8  0.47 13.20 0.029 7
HPV67  2  3.8  0.47 13.20 0.029 7
HPV68  1  1.9  0.05 10.25 0.110 0
HPV73  1  1.9  0.05 10.25 0.110 0
Low risk HPV6  1  1.9  0.05 10.25 0.110 0
HPV69  2  3.8  0.47 13.20 0.029 7
HPV70  1  1.9  0.05 10.25 0.110 0
HPV44  1  1.9  0.05 10.25 0.110 0
HPV90  1  1.9  0.05 10.25 0.110 0
Others HPV34  1  1.9  0.05 10.25 0.110 0
HPV71  5  9.6  3.20 21.00 0.001 1
HPV91  1  1.9  0.05 10.25 0.110 0
Total 52      100.0
   We observed an age-related distribution of viral risk 
genotypes (Figure 1). Thus, only high risk genotypes were 
found in the 18-24 years of age group, while in women over 
55 years only 1 out of 5 HPV viruses detected belonged to 
this risk group. The women between 25 and 54 years of age 
showed a large diversity of genotypes, while in the 25-34 
years group the highest genotype dispersion was observed. 
In addition, a progressive increase in the incidence of HPV16 
was observed in the 18-24, 25-34 and 35-44 year groups 
(3.8%, 9.6% and 21.2%, respectively).
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Figure 1. Distribution of HPV genotypes in age groups of the population of 
asymptomatic women.
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   Using the PAP method we detected 13 samples presenting 
tissue lesions, 9 being associated with the presence of 
HPV (Table 3). A positive correlation (Pearson coefficient, 
r=0.993 4) between the uterine tissue lesion and the presence 
of HPV in tissue, was found, with a relationship between 
the two variables as shown in Table 3 (P=0.472 4, χ2-test). 
Regarding the association between lesions and specific 
genotypes, it was found that the ASCUS lesion was partially 
related to the HPV66 genotype, while LSIL was related to the 
HPV16 genotype. HSIL was the most frequent lesion among 
PAP positive samples being related to several HPV genotypes 
(HPV16, 71, 91 and 39).
Table 3
Presence of HPV genotypes in PAP positive cervical lesions.
Lesion PAP smear
N (%)
PCR
N (%)
Viral genotype
ASCUS 2 (15.38)    1 (11.11) HPV66
LSIL (CIN 1) 4 (30.77)    2 (22.22) HPV16
HSIL (CIN 2–CIN 3) 7 (53.85)    3 (33.33) HPV16
   1 (11.11) HPV71
   1 (11.11) HPV91
   1 (11.11) HPV39
Total 13 (100.00) 9 (100.00)
   Regarding the risk factors analyzed the most relevant were 
the number of sexual partners. Thus, the percentage of HPV+ 
women belonging to each group increased from 8.1% (women 
with 1 sexual partner) to 40.9% (women with >3 sexual 
parterns), with the OR progressively increasing (0.71, 0.94 and 
3.04) according to the increase in the number of partners: 1, 
2, and >3, respectively (Table 4). 
Table 4
Association between the presence of HPV and risk factors in the 
population of asymptomatic women.
Group Frequency N (%) OR 95% CI Z-test 
(P)Total (n=254) HPV positive 
(n=52)
HPV negative 
(n=202)
Lower Upper
Age range
18-24       24 (9.4) 4 (7.7)       20 (9.9) 0.76 0.25 2.32 0.022 9
25-34 77 (30.3) 20 (38.5) 57 (28.2) 1.59 0.84 3.01 0.998 6
35-44 79 (31.1) 16 (30.8) 63 (31.2) 0.98 0.51 1.90 0.959 9
45-54 47 (18.5)   7 (13.5) 40 (19.8) 0.63 0.26 1.50 0.144 2
>55 27 (10.6)         5 (9.6) 22 (10.9) 0.87 0.31 2.42 0.045 9
Age of first coitus
<17 80 (31.5) 24 (46.2) 56 (12.4) 2.23 1.19 4.18 0.994 3
18-24    116 (45.6) 23 (44.2) 93 (46.0) 0.93 0.50 1.72 0.990 5
25-34      21 (8.3) 2 (3.8)       19 (9.1) 0.39 0.09 1.71 0.059 0
>35       2 (0.8) 0 (0.0) 2 (1.0) - - - -
No data 35 (13.8) 3 (5.8) 32 (15.8) - - - -
Number of sexual partners since firts coitus
1 partner    144 (56.6) 26 (50.0)     118 (58.4) 0.71 0.39 1.31 0.997 1
2 partners 55 (21.6) 13 (25.0) 42 (20.8) 0.94 0.46 1.92 0.500 0
>3 partners      22 (8.7)   9 (17.3)       12 (5.9) 3.04 1.22 7.58 0.197 5
No data 33 (13.0) 4 (7.7) 29 (14.4) - - - -
Parity
0      17 (6.7) 4 (7.7)       13 (6.4) 1.21 0.38 3.88 0.005 4
1 43 (16.9)  8 (15.4) 35 (17.3) 0.87 0.38 2.00 0.666 7
2 50 (19.7)  6 (11.5) 44 (21.8) 0.47 0.19 1.17 0.143 7
3 44 (17.3) 15 (28.8) 29 (14.4) 2.42 1.18 4.96 1.000 0
4      22 (8.7)  6 (11.5)       16 (7.9) 1.52 0.56 4.09 0.142 9
>5 40 (15.7)  7 (13.5) 33 (16.3) 0.80 0.33 1.92 0.374 4
No data 38 (15.0)  6 (11.5) 32 (15.8) - - - -
No clear relationship was observed between age or parity 
with HPV infection. Thus, despite 38.5% (20 cases) of the 
positive HPV cases belonging to women between 25 and 34 
years of age, these cases represented 26% of the women 
belonging to this age group, being a similar percentage to 
that detected in the remaining groups.
4. Discussion
   HPV infection is a common sexually transmitted disease 
which is usually benign, but its persistence over time 
and continuous exposure to the virus may lead to the 
development of cervical cancer[22-24]. This cancer is very 
common among women and is the leading cause of death in 
economically active women especially in low- and middle-
income countries[4]. In Peru, cervical cancer is first among 
all the female malignancies and is mainly associated with 
HPV infection. However, there are no studies showing 
prevalence of the HPV in the asymptomatic population. Thus, 
early diagnosis and prevention is relevant to diminish its 
mortality by this disease[25].
   The present results showed a remarkably high prevalence 
of HPV infection in an Andean population in Northern Peru. 
In this population, as in the rest of Latin America, only 
PAP is used as the screening method. However, the present 
data demonstrate that this technique has a low sensitivity. 
On the other hand, using the PCR method showed a higher 
prevalence (46.2%) of HPV infection in young asymptomatic 
women of 25-44 years of age, which is higher than that 
reported in other Latin American countries, such as Mexico 
(14.5%), Costa Rica (16.0%) and Colombia (14.8%)[26-28]. 
Although few studies on prevalence of HPV in asymptomatic 
women has reported a high prevalence of HPV detected by 
PCR[29], in our population an infrequent high prevalence of 
HPV among asymptomatic women is present. One explanation 
for this higher prevalence may be related to an historical low 
interchange of population.
   The prevalence of HPV diagnosed using the PAP method 
was 5.1%. Among these samples, different cervical tissue 
lesions were detected using the Bethesda system. The high 
percentage of false negatives obtained by the PAP method 
indicates that this is not a good screening method for early 
detection of HPV infection; Minimal morphological changes 
can be so subtle that they can easily go unnoticed. The low 
sensitivity of the PAP method highlights the need for a rapid, 
affordable, accurate and sensitive method to detect and 
differentiate HPV genotypes which is essential to identify 
high risk patients, who are otherwise found to have a normal 
cytology by PAP smear.
   In general, high risk genotypes are closely related to the 
development of cervical cancer[7,8]. Wang et al. reported that 
HPV16, 18 and 45 genotypes are more likely to be integrated 
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into the human genome than other HPV genotypes, thereby 
facilitating early tumors developments[30]. In addition, 
the relation between HPV16 and 18 infections and the 
risk of developing high-grade cervical lesions has been 
described[2,31,32]. In the present study, a high frequency 
of HPV16 (38.5%) was observed, in accordance with that 
described in other Peruvian areas[33]. This fact, together with 
the above mentioned relevance of HPV16 again highlights 
the need to introduce more adequate diagnostic methods. 
The present results also support the introduction of HPV 
vaccination in Peru[34]. Regarding prevalence of other 
genotypes strong differences were found. Thus Montano et 
al. also showed a high prevalence of other 4 HPV genotypes 
HPV6, 51, 53, 62 (22.7%, 20.5%, 18.2% and 15.9% respectively)
[33], while in our study accounting for 1.9% each, except 
HPV62, which was not detected. These differences which 
may be explained by the aforementioned low interchange of 
population highlights the need to dispose of a more complete 
scenario of the current distribution of HPV genotypes, 
including that of rural areas.
   The use of PCR showed a frequency of HPV of 20.5%, in 
the population analyzed, supporting the routine use of 
PCR to better determine the presence of HPV infection 
in endocervical samples prior to lesion development. 
Nonetheless, PAP screening rates are reportedly low in Peru, 
around of 31% in urban areas and lower in rural areas[35], and 
thus in order to achieve correct implementation of screening 
for HPV, population awareness of the severe consequence of 
this disease is necessary.
   The age at which the first sexual relationship has taken 
place has a direct relationship with HPV infection. In 
this study, a prevalence of 30.0% and 19.8% was observed 
in women who had had their first intercourse when 
younger than 17 years and in the age group of 18-24 years, 
respectively. This prevalence is higher than that reported 
in a study of Chilean women (Santiago de Chile), in which 
the prevalence of HPV was 14% in this age group[17,36,37]. It 
is well established that the most important risk factor for 
acquiring HPV infection is sexual activity[38]. In accordance 
to our study the number of lifetime sex partners has a direct 
effect on the risk of HPV acquisition. In the same line, albeit 
not analyzed in our data, another relevant variable affecting 
a woman’s risk of HPV infection is the number of current 
and previous partners of her partner[39,40]. It has also been 
indicated that high parity is another risk factor associated 
with cervical cancer[41,42]. Although our data suggest that 
this may be true in women with 3-4 children, no definitive 
conclusion may be made.
   These results will be useful for correct clinical diagnosis 
and prevention of cervical cancer due to early detection of 
HPV infection. Cervical cancer can be prevented and cured 
at both a low cost and risk as long as screening to facilitate 
early detection of precursor lesions, early diagnosis and 
appropriate treatment and follow up is available to all 
sectors of society.
   In summary, our results demonstrate that PCR amplification 
allows detection of HPV infections more efficiently than 
PAP. Identification of the specific HPV genotype before 
evident cervical histological changes occur will allow the 
implementation of corrective or appropriate prophylactic 
measures and will have a direct impact on the natural 
history of the disease and subsequent development of 
cervical malignancy.
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